https://orcid.org/0000-0002-1032-5808
Figures & data
Figure 1. FcɣRIIIa affinity chromatography for a therapeutic mAb. (a) UV chromatogram using reported non-MS compatible conditions. (b) AC-MS under MS-compatible conditions represented by extracted ion chromatograms of detected glycoforms. (c and d) Deconvoluted mass spectra and charge state distribution (inserts) of (c) 2x fucosylated (18– 34 min) and (d) remaining glycoforms (34– 42 min). In case of multiple possibilities (asterisk), the most probable glycoform is presented, based on reference data (Supplemental Table 7); all possible glycoforms and their structures are listed in Supplemental Table 1 and 4.
Figure 2. Extracted ion chromatograms of AC-MS with glycoengineered mAbs containing a high level of bisected and afucosylated glycoforms (a) and high level of bisected and fucosylated glycoforms (b). Increased affinity is observed for afucosylation compared to 1x (a)fucosylation. Bisected fucosylated glycoforms showed also increased affinity compared to non-bisected fucosylated glycoforms. Positive effect of galactosylation is represented for each glycosylation feature.
